{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:27Z","timestamp":1790742507905,"version":"4.1.0"},"reference-count":10,"publisher":"Copernicus GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:00:00Z","timestamp":1551484800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Bone Joint Infect."],"abstract":"<jats:p>Abstract. Purpose: To compare safety and efficacy of Vancomycin (Van) versus Daptomycin (Dap) as post-operative empirical antibiotic treatment (PEAT) in patients with periprosthetic joint infections (PJIs).Methods: Medical charts of patients treated empirically with Van or Dap in the post-operative period of total hip\/knee prosthesis septic revision until the results of intra-operative culture were reviewed. Cefotaxime, cefepime or aztreonam were used in combination with Dap or Van.Results: Twenty Dap patients were matched with 20 other Van patients according to the age and type of prosthesis. The ASA score and the distribution of the pathogens was similar in the two groups especially regarding the number of methicillin-resistant staphylococci. The mean duration of the PEAT was 6.07 \u00b1 0.85 days. A total of 17 episodes of adverse events (AE) in 10 patients (25%) were recorded during the PEAT which led to discontinue the treatment in 5 patients, all of them treated with Van (P=0.02). At the end of a mean post-treatment follow-up of 618 +\/- 219 days, 36 patients remained in remission of infection; 2 patients failed in each group.Conclusions: Our observations suggest that PEAT with Van for septic revision of PJIs is associated with a higher discontinuation rate due to AE but with a similar outcome than it is with Dap.\n                    <\/jats:p>","DOI":"10.7150\/jbji.22118","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T06:45:47Z","timestamp":1553237147000},"page":"72-75","source":"Crossref","is-referenced-by-count":13,"title":["Daptomycin versus Vancomycin as Post-Operative Empirical Antibiotic Treatment for Prosthetic Joint Infections: A Case-Control Study"],"prefix":"10.5194","volume":"4","author":[{"given":"C","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Robineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Titecat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Blondiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Loiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JL","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"D\u00e9zeque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Migaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Senneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3145","published-online":{"date-parts":[[2019,3,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Osmon DR, Berbari EF, Berendt AR, et al.; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1\u201310.","DOI":"10.1093\/cid\/cis966"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Senneville E, Joulie D, Legout L. et al. Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53:334\u201340. [PMC free article]","DOI":"10.1093\/cid\/cir402"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tit\u00e9cat M, Senneville E, Wallet F, Dez\u00e8que H, Migaud H, Courcol RJ, Lo\u00efez C. Microbiologic profile of Staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect (Larchmt) 2015;16:77\u201383.","DOI":"10.1089\/sur.2013.258"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Herrera J, Docobo-P\u00e9rez F, L\u00f3pez-Rojas R. et al. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 2012;56:613\u20137. [PMC free article]","DOI":"10.1128\/AAC.05606-11"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Murillo O, Garrigos C, Pachon ME. et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009;53:4252\u20137. [PMC free article]","DOI":"10.1128\/AAC.00208-09"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Senneville E, Caillon J, Calvet B. et al. Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents. 2016;47:12\u20139.","DOI":"10.1016\/j.ijantimicag.2015.11.005"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645.","DOI":"10.1056\/NEJMra040181"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mehta RL, Kellum JA, Shah SV, et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31. [PMC free article]","DOI":"10.1186\/cc5713"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ingram PR, Lye DC, Tambyah PA. et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62:168\u201371.","DOI":"10.1093\/jac\/dkn080"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney International. 2010;77:760\u20134.","DOI":"10.1038\/ki.2010.35"}],"container-title":["Journal of Bone and Joint Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jbji.copernicus.org\/articles\/4\/72\/2019\/jbji-4-72-2019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T09:20:07Z","timestamp":1596532807000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbji.copernicus.org\/articles\/4\/72\/2019\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,2]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.7150\/jbji.22118","relation":{},"ISSN":["2206-3552"],"issn-type":[{"value":"2206-3552","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,2]]}}}